Epidermal Growth Factor Receptor variant III (EGFRvIII) chimeric antigen receptor T cells

Star0

DB18654InvestigationalCell transplant therapies

Epidermal Growth Factor Receptor variant III (EGFRvIII) chimeric antigen receptor T cells: Overview.

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed
Also known as: Autologous Chimeric Antigen Receptor (CAR) Modified Recombinant T Cells Targeting EGFRvIII · EGFRvIII CAR-T

Resolves to

Targets

P00533EGFR

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Epidermal Growth Factor Receptor variant III (EGFRvIII) chimeric antigen receptor T cells, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account